Perrigo Co. announced Monday it was voluntarily recalling two flavors of children's cough syrup sold as store brands at various stores, including Dollar General, Bi-Lo, Rite-Aid, Amazon and CVS. The reason for the recall is because incorrectly labeled dosing cups could put children at risk for overdose.
Specifically, it is recalling children's guaifenesin grape liquid (100mg/5 mL) and children's guaifenesin DM cherry liquid (100mg guaifenesin and 5mg dextromethorphan HBr/ 5 ml) sold in 4 oz. bottles with dosage cups in boxes.
The company warns that symptoms of an overdose include hyper excitability, nausea, irregular heartbeat, rapid eye movements, changes in muscle reflexes, ataxia, dystonia, hallucinations, stupor and coma.
"There have been no reports of adverse events to Perrigo as a result of the incorrect dosage markings," said Joseph C. Papa, the company's chairman and CEO. "Perrigo is taking this action to maintain the highest possible product quality standards for our retail customers and consumers. We are taking this action because it is the right thing to do."
Consumers that have products affected by the recall should discard the entire product and can call Perrigo at 1-888-345-0479 8 a.m.-10 p.m. Mondays through Fridays, or visit mucusreliefrecall.com. Consumers should contact their physician or healthcare provider if they suspect an overdose has occurred.
The following products are listed as part of the recall:
GUAIFENESIN GRAPE LIQ 4 OZ:
H.E.B. — 5LK0592, expires 08/2017
CVS — 5MK0340, expires 08/2017
GUAIFENESIN DM CHRY LIQ 4 OZ:
Sunmark —5LK0528, 5LK0630, expires 03/2017
Rite-Aid — 5LK0528, 5LK0630, expires 03/2017
Topcare — 5LK0528, 5LK0630, 5LK0779, expires 03/2017
Kroger — 5LK0528, 5LK0630, expires 03/2017
GoodSense — 5LK0528, expires 03/2017
Dollar General — 5LK0630, expires 03/2017
Care One — 5LK0630, expires 03/2017
CVS — 5LK0630, expires 03/2017
More information can be found online at Perrigo's website
.
Join the Conversation
To find out more about Facebook commenting please read the Conversation Guidelines and FAQs
Comments